For the Inventor, By the Inventor

Enter assignee name

Zug, Switzerland

Baxalta Gmbh

USPTO Granted Patents = 153

% Expired Patents = 17.0

CIPO Patents = 48

EPO Patents = 106

Trademarks = 2

Forward Citations = 501

Loading Chart...

Loading Chart...

243 inventors (with patents filed for the assignee):

Hans-Peter Schwarz (58 out of 107 patents)

Manfred Reiter (54 out of 71 patents)

Peter Turecek (52 out of 120 patents)

4. Friedrich Scheiflinger (46 out of 76 patents)

5. Leopold Grillberger (46 out of 42 patents)

6. Hanspeter Rottensteiner (34 out of 35 patents)

7. Wolfgang Mundt (32 out of 63 patents)

8. Wolfgang Teschner (30 out of 35 patents)

9. Michael Dockal (30 out of 31 patents)

10. Meinhard Hasslacher (29 out of 35 patents)

11. Artur Mitterer (23 out of 53 patents)

12. Alfred Weber (20 out of 28 patents)

13. Juergen Siekmann (20 out of 45 patents)

14. Friedrich Dorner (18 out of 91 patents)

15. Harald Arno Butterweck (16 out of 18 patents)

Core Competencies:

Factor VIII

ADAMTS13

von Willebrand Factor

Biologically Active Peptides

Gene Therapy

Protein Purification

Chromatographic Methods

Hemophilia

Cell Culture

Immunoglobulin G

TFPI Inhibitors

Nucleophilic Catalysts

153 patents: Sort by Forward Citations

1. 12622950 - TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF (2026-05-12),

2. 11305000 - Chimeric OspA genes, proteins and methods of use thereof (2022-04-19),

3. 11081211 - Method and apparatus for providing a pharmacokinetic drug dosing regimen (2021-08-03),

4. 11020459 - Factor VIII formulations (2021-06-01),

5. 10934340 - Separation of VWF and VWF propeptide by chromatographic methods (2021-03-02),

6. 10905746 - Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF (2021-02-02),

7. 10900979 - Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD) (2021-01-26),

8. 10875906 - Removal of serine proteases by treatment with finely divided silicon dioxide (2020-12-29),

9. 10842853 - Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B (2020-11-24),

10. 10822394 - Method of producing recombinant high molecular weight vWF in cell culture (2020-11-03),

11. 10822376 - Biologically active peptides (2020-11-03),

12. D898342 - Carrying case (2020-10-13),

13. 10800816 - TFPI inhibitors and methods of use (2020-10-13),

14. 10772968 - Glycopolysialylation of non-blood coagulation proteins (2020-09-15),

15. 10758599 - Stabilized liquid and lyophilized ADAMTS13 formulations (2020-09-01),

Company Overview

Baxalta GmbH, headquartered in Zug, Switzerland, specializes in the development and manufacturing of innovative therapies for blood coagulation disorders. The company focuses on critical areas such as Factor VIII, ADAMTS13, and von Willebrand Factor, contributing significantly to the treatment of hemophilia and related conditions. Baxalta is also engaged in advanced research on biologically active peptides, gene therapy, and protein purification techniques, utilizing sophisticated chromatographic methods to enhance therapeutic efficacy.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

153 Patents

#7 in Zug

#120 in Switzerland

#5,338 in the World

Zug, Switzerland

Baxalta Gmbh

Forward Citations = 501

243 inventors:

Hans-Peter Schwarz (58 out of 107 patents)

Manfred Reiter (54 out of 71 patents)

Peter Turecek (52 out of 120 patents)

4. Friedrich Scheiflinger (46 out of 76 patents)

5. Leopold Grillberger (46 out of 42 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Baxalta Gmbh. Retrieved from https://idiyas.com/company/baxalta

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…